Hepatitis/MASH

Panel suggests different regimens for different hepatitis C patient groups.

Hope on the horizon for patients with liver damage.

Researchers seek a better understanding of the mechanism behind hepatocellular carcinoma.

Risk for illness and death greater due to socioeconomic status of patients with hepatitis C.

Gilead alleged to have priced and marketed Sovaldi to maximize revenue without regard to consequences for patients.

Statins show promise to reduce liver disease incidence in coinfected patients.

Traveling a longer distance to a medical center was not associated with spending more time on a waiting list.

Liver conserving treatments are sorely needed.

Research may lead to gel that prevents transmission of HIV, hepatitis C and the Ebola virus.

An HCV vaccine, while elusive, offers the best hope to eradicate the virus.

Eating before bed can have a significant impact on the development of nonalcoholic fatty liver disease.

Researchers consider the ramifications of using organs from infected patients to save lives.

Liver damage caused by hepatitis C may eventually be overcome through stem cell therapy.

Enhanced screening and treatment in high-risk populations could eliminate virus.

Clean needle programs have reduced HIV incidence among injection drug abusers by 80% from 1990 to 2006.

New models of collaboration can guide providers in optimizing care for patients with HCV.

Early treatment found to be cost-effective compared with waiting until liver fibrosis worsens.

Successful response to hepatitis C treatment shows a 30 percent increased reduction in liver stiffness.

The FDA is taking into consideration a once-daily formulation of AbbVie's ombitasvir, paritaprevir, and ritonavir tablets co-packaged with dasabuvir tablets (Viekira Pak).

Researchers determine how the liver is able to naturally inhibit HCV infection.

Scientists discover threat from AAV2 virus and from correlation to the development of liver cancer.

Recent case reports indicate possible anti-lymphoma efficacy of direct-acting antivirals in patients with both lymphoma and hepatitis C.

Recent case reports indicate possible anti-lymphoma efficacy of direct-acting antivirals in patients with both lymphoma and hepatitis C.

Likelihood of co-infection linked closely to intravenous drug use more often than risky sexual activities in patients with HIV and hepatitis C.